The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Blocking - Blocking peptide for Anti-CGRP antibody (ab47027)
- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions. - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer. - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent. - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised. - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Information available upon request.
Calcitonin/calcitonin related polypeptide alpha
Alpha type CGRP
Beta type CGRP
Calcitonin gene related peptide I
Calcitonin gene related peptide II
Calcitonin related polypeptide alpha
Calcitonin related polypeptide beta
CGRP is present in C-cells of the thyroid and in central and peripheral nerves. CGRP has several important physiologic roles: it is a potent vasodilator, and can affect the force and rate of heart beat; it can modulate acetylcholine receptor function at the neuromuscular junction; it has been demonstrated to block tolerance to morphine; and it can modulate antigen presentation in Langerhans cells in the skin. Despite these important physiologic functions, therapeutic strategies using CGRP have been impeded due to the lack of a cloned CGRP receptor with which ligands could be developed.
Endoplasmic reticulum and Secreted
References for Rat CGRP peptide (ab47101)
This product has been referenced in:
Tzabazis A et al. Oxytocin receptor: Expression in the trigeminal nociceptive system and potential role in the treatment of headache disorders. Cephalalgia36:943-50 (2016).
Read more (PubMed: 26590611) »
Harrington AM et al. Sprouting of colonic afferent central terminals and increased spinal MAP kinase expression in a mouse model of chronic visceral hypersensitivity. J Comp Neurol : (2012).
Read more (PubMed: 22237807) »